254 related articles for article (PubMed ID: 37629188)
1. Diagnosis- and Prognosis-Related Gene Alterations in
Morishita S; Komatsu N
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629188
[No Abstract] [Full Text] [Related]
2. Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing.
Easwar A; Siddon AJ
Life (Basel); 2021 Oct; 11(11):. PubMed ID: 34833034
[TBL] [Abstract][Full Text] [Related]
3. Chronic myeloproliferative neoplasms with concomitant
Zanelli M; Fragliasso V; Loscocco GG; Sanguedolce F; Broggi G; Zizzo M; Palicelli A; Ricci S; Ambrogi E; Martino G; Aversa S; Coppa F; Gentile P; Gozzi F; Caltabiano R; Koufopoulos N; Asaturova A; Cimino L; Cavazza A; Orcioni GF; Ascani S
Front Cell Dev Biol; 2024; 12():1391078. PubMed ID: 38596359
[TBL] [Abstract][Full Text] [Related]
4. The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.
Lin Y; Liu E; Sun Q; Ma J; Li Q; Cao Z; Wang J; Jia Y; Zhang H; Song Z; Ai X; Shi L; Feng X; Li C; Wang J; Ru K
Am J Clin Pathol; 2015 Jul; 144(1):165-71. PubMed ID: 26071474
[TBL] [Abstract][Full Text] [Related]
5. [Detection and Diagnostic Values of JAK2, CALR, MPL Gene Mutations in 208 Cases of BCR/ABL1 Negative Chronic Myeloproliferative Diseases].
Li ZL; Gao L; Zhang H; Zhang CX; Chen YR; Huang FZ; Gong M; Gao YY; Tang Y; Ma YG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1122-1128. PubMed ID: 30111418
[TBL] [Abstract][Full Text] [Related]
6. Rare Case of Accelerated-Phase Chronic Myeloid Leukemia Diagnosed During Treatment for JAK2 V617F-Positive Primary Myelofibrosis.
Ryu J; Chu D; Park B; Kim M; Cho YU; Hwang SH; Jang S; Seo EJ; Lee JH; Park CJ
Lab Med; 2022 Nov; 53(6):e140-e144. PubMed ID: 35243502
[TBL] [Abstract][Full Text] [Related]
7. [Clinical impact of gene mutations on myeloproliferative neoplasms in Japan].
Morishita S
Rinsho Ketsueki; 2021; 62(8):1060-1069. PubMed ID: 34497192
[TBL] [Abstract][Full Text] [Related]
8. A link between the driver mutations and dysregulated apoptosis in BCR-ABL1 negative myeloproliferative neoplasms.
Mambet C; Matei L; Necula LG; Diaconu CC
J Immunoassay Immunochem; 2016; 37(4):331-45. PubMed ID: 26890068
[TBL] [Abstract][Full Text] [Related]
9. Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.
Yue Y; Wei W; Guo Y; Wang F; Dong W; Liu Y; Lin Y; Cao Y; Gu W
Am J Case Rep; 2020 Oct; 21():e925151. PubMed ID: 33021971
[TBL] [Abstract][Full Text] [Related]
10. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.
Soderquist CR; Ewalt MD; Czuchlewski DR; Geyer JT; Rogers HJ; Hsi ED; Wang SA; Bueso-Ramos CE; Orazi A; Arber DA; Hexner EO; Babushok DV; Bagg A
Mod Pathol; 2018 May; 31(5):690-704. PubMed ID: 29327708
[TBL] [Abstract][Full Text] [Related]
11. Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of
Abbou N; Piazzola P; Gabert J; Ernest V; Arcani R; Couderc AL; Tichadou A; Roche P; Farnault L; Colle J; Ouafik L; Morange P; Costello R; Venton G
Cells; 2022 Dec; 12(1):. PubMed ID: 36611899
[No Abstract] [Full Text] [Related]
12. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
13. Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms.
Zhao Y; Reddi D; McCracken J; Iranzad N; Rehder C; Neff J; Wang E
Arch Pathol Lab Med; 2022 Jun; 146(6):710-717. PubMed ID: 34506622
[TBL] [Abstract][Full Text] [Related]
14. Co-occurrence of
Zanelli M; Bisagni A; Sanguedolce F; Broggi G; Fragliasso V; Zizzo M; Palicelli A; Martino G; Cresta C; Caprera C; Corsi M; Gentile P; Gozzi F; Trombetta D; Parente P; Caltabiano R; Koufopoulos N; Cimino L; Cavazza A; Fraternali Orcioni G; Ascani S
Front Oncol; 2023; 13():1329298. PubMed ID: 38282677
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of the clinical features of 172 patients with
Lin X; Huang H; Chen P
Mol Cytogenet; 2020; 13():8. PubMed ID: 32095159
[TBL] [Abstract][Full Text] [Related]
16. Genomic alterations in blast phase of BCR::ABL1-negative myeloproliferative neoplasms.
Chen D; Weinberg OK
Int J Lab Hematol; 2023 Dec; 45(6):839-844. PubMed ID: 37867386
[TBL] [Abstract][Full Text] [Related]
17. [Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies].
Takenaka K
Rinsho Ketsueki; 2016; 57(10):1944-1955. PubMed ID: 27725592
[TBL] [Abstract][Full Text] [Related]
18. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
[TBL] [Abstract][Full Text] [Related]
19. pSTAT3/pSTAT5 Signaling Patterns in Molecularly Defined Subsets of Myeloproliferative Neoplasms.
Sakr H; Clark Schneider K; Murugesan G; Bodo J; Hsi ED; Cook JR
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):147-152. PubMed ID: 27258562
[TBL] [Abstract][Full Text] [Related]
20. Development of a Real-Time qPCR Assay for Detection of Common MPL Mutations in Myeloproliferative Neoplasms (MPNS).
Ullah N; Khan SN; Umair M; Khan AA; Liu X; Khattak AA; Yousafzai YM
Appl Biochem Biotechnol; 2022 Dec; 194(12):5907-5917. PubMed ID: 35838887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
